Antibiotics: Longer treatment times that benefit children may cost society

Sep 08, 2010

The likelihood that the treatment of a middle ear infection will fail is slightly higher for a child who is given a shorter course of antibiotics, according to a new Cochrane Systematic Review. The results are conclusive, but the researchers say there are other factors that must be considered when the drugs are prescribed.

Most suffer at some point from a middle ear infection, also called acute otitis media (AOM). It is one of the most common reasons for children being prescribed antibiotics, at a cost of up to $5 billion each year in the US alone. Health practitioners vary in the length of course that they prescribe to treat the infection. The standard course in Britain is five days, whereas in North America it is ten. Due to concern about caused by overuse, and the increasing cost of providing these drugs, the researchers decided to update a previous Cochrane Review carried out in 2000.

The updated review included 49 trials involving 12,045 children aged one month to 18 years, 22 of which were studies that had not been included in the original review. According to results, the likelihood of treatment failure with long course antibiotics was one in six compared to one in five with short course antibiotics. Long course was defined as more than one week, whereas short course was defined as less than one week. The researchers concluded that the policy of treating for five days might slightly increase the risk of a child experiencing further symptoms, or a relapse, in the second to third week after starting treatment.

According to the researchers, their work has not changed the findings of the original review and further updates should not be needed. "Any new studies would not change the current outcomes," said lead researcher Terry Klassen, Director of Research, Manitoba Institute of Child Health, the research division of the Children's Hospital Foundation of Manitoba.

"However, it is up to clinicians to assess whether it is worth exposing children to a longer course for the sake of a slightly reduced risk of failure in the short term," said Klassen. "Shorter courses can be safely used and generally produce fewer side effects. It is more difficult to support longer term use of antibiotics on the basis of their cost and especially considering concerns over the effects of indiscriminate use of on resistance."

Explore further: FDA OKs Cubist antibiotic for serious infections

add to favorites email to friend print save as pdf

Related Stories

Antibiotic use in infants linked to asthma

Jun 11, 2007

New research indicates that children who receive antibiotics before their first birthday are significantly more likely to develop asthma by age 7. The study, published in the June issue of CHEST, the peer-reviewed journal ...

Antibiotics found to increasingly fail

Apr 09, 2007

Pediatricians in the United States are increasingly finding that antibiotics are not always ideal for treating ear infections, a report says.

Antibiotic resistance lasts up to a year

May 18, 2010

Patients prescribed antibiotics in primary care may develop a resistance that lasts up to 12 months, according to research published in the British Medical Journal today.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.